Adtalem Q2 revenue up 12.4%, beats estimates

Reuters
Jan 29
Adtalem <a href="https://laohu8.com/S/QTWO">Q2</a> revenue up 12.4%, beats estimates

Overview

  • Healthcare educator's Q2 revenue rose 12.4% yr/yr, beating analyst expectations

  • Adjusted EPS grew 34.3% yr/yr

  • Company announced new $750 mln share repurchase program

Outlook

  • Adtalem maintains fiscal year 2026 revenue guidance at $1,900 mln to $1,940 mln

  • Company raises fiscal year 2026 adjusted EPS guidance to $7.80-$8.00

  • Adtalem to host Investor Day on February 24, 2026

Result Drivers

  • ENROLLMENT GROWTH - Total student enrollment increased 6.3% YoY, marking the tenth consecutive quarter of growth, driven by Walden University's 13% enrollment rise

  • WALDEN UNIVERSITY PERFORMANCE - Walden University achieved a 13% YoY increase in enrollment, contributing to a 27% revenue growth

  • CHAMBERLAIN UNIVERSITY INITIATIVES - Chamberlain University continued pre-licensure BSN enrollment growth

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Beat

$503.40 mln

$488.73 mln (4 Analysts)

Q2 Net Income

$76.40 mln

Q2 Adjusted EBITDA

Beat

$154.90 mln

$139.09 mln (3 Analysts)

Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the miscellaneous educational service providers peer group is "buy."

  • Wall Street's median 12-month price target for Adtalem Global Education Inc is $166.50, about 44.5% above its January 27 closing price of $115.22

  • The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 19 three months ago

Press Release: ID:nBw22rV2Sa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10